Department of Radiology, Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Sci Rep. 2024 May 14;14(1):10985. doi: 10.1038/s41598-024-61925-3.
Several prognostic factors are known to influence survival for patients treated with IDH-wildtype glioblastoma, but unknown factors may remain. We aimed to investigate the prognostic implications of early postoperative MRI findings. A total of 187 glioblastoma patients treated with standard therapy were consecutively included. Patients either underwent a biopsy or surgery followed by an early postoperative MRI. Progression-free survival (PFS) and overall survival (OS) were analysed for known prognostic factors and MRI-derived candidate factors: resection status as defined by the response assessment in neuro-oncology (RANO)-working group (no contrast-enhancing residual tumour, non-measurable contrast-enhancing residual tumour, or measurable contrast-enhancing residual tumour) with biopsy as reference, contrast enhancement patterns (no enhancement, thin linear, thick linear, diffuse, nodular), and the presence of distant tumours. In the multivariate analysis, patients with no contrast-enhancing residual tumour or non-measurable contrast-enhancing residual tumour on the early postoperative MRI displayed a significantly improved progression-free survival compared with patients receiving only a biopsy. Only patients with non-measurable contrast-enhancing residual tumour showed improved overall survival in the multivariate analysis. Contrast enhancement patterns were not associated with survival. The presence of distant tumours was significantly associated with both poor progression-free survival and overall survival and should be considered incorporated into prognostic models.
已知一些预后因素会影响 IDH 野生型胶质母细胞瘤患者的治疗效果,但可能仍存在未知因素。我们旨在研究术后早期 MRI 结果的预后意义。共连续纳入 187 例接受标准治疗的胶质母细胞瘤患者。这些患者要么接受活检,要么接受手术和术后早期 MRI。使用神经肿瘤学反应评估 (RANO)-工作组(无对比增强残留肿瘤、不可测量对比增强残留肿瘤或可测量对比增强残留肿瘤)的活检作为参考,对已知的预后因素和 MRI 衍生的候选因素(无增强、线性薄、线性厚、弥漫、结节状)进行无进展生存期(PFS)和总生存期(OS)分析,并分析了远处肿瘤的存在情况。在多变量分析中,与仅接受活检的患者相比,术后早期 MRI 显示无对比增强残留肿瘤或不可测量对比增强残留肿瘤的患者 PFS 显著改善。仅在多变量分析中,具有不可测量对比增强残留肿瘤的患者 OS 得到改善。对比增强模式与生存无关。远处肿瘤的存在与不良的 PFS 和 OS 显著相关,应考虑将其纳入预后模型。